2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
05/10/17REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
ROCKVILLE, Md., May 10, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In additi... 
Printer Friendly Version
05/09/17REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017 and continuing enrollment of patients in RGX-501 Phase I/II trial for HoFH Interim trial updates for RGX-314 and RGX-501 anticipated by year-end 2017 $210 million in cash, cash equivalents and marketable securities as of March 31, 2017 ROCKVILLE, Md., May 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the ... 
Printer Friendly Version
05/04/17Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
Preclinical data for RGX-314 program for the treatment of wet AMD to be presented at the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and the American Society for Gene and Cell Therapy Data support the active IND for RGX-314 Phase I clinical trial    ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative poten... 
Printer Friendly Version
05/02/17REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights. To access the live call by phone, dial (855) 422-... 
Printer Friendly Version
04/26/17REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the underwriters of REGENXBIO’s public offering of common stock have purchased an additional 555,000 shares of common stock at a price of $20.50 per share, before deducting the underwriting discount, in connection with the exe... 
Printer Friendly Version
03/28/17REGENXBIO Enhances and Expands Scientific Leadership
Appoints Gene Therapy Industry Leader Olivier Danos, Ph.D., as Chief Scientific Officer ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that Olivier Danos, Ph.D., is joining REGENXBIO in the newly created position of Chief Scientific Officer. Dr. Danos will report to Kenneth T.... 
Printer Friendly Version
03/21/17REGENXBIO Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md., March 21, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at the price of $20.50 per share before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deduct... 
Printer Friendly Version
03/21/17REGENXBIO Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md., March 21, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $75,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whethe... 
Printer Friendly Version
03/07/17REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
IND for RGX-314 Phase I trial for wet AMD is active and dosing initiated for RGX-501 Phase I/II trial for HoFH Interim trial updates for RGX-314 and RGX-501 expected by year-end 2017 $159 million in cash, cash equivalents and marketable securities as of December 31, 2016 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its pro... 
Printer Friendly Version
03/07/17REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia
First AAV gene therapy treatment for HoFH; interim trial update expected late 2017 ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the first patient in a Phase I/II clinical trial of REGENXBIO’s investigational gene therapy RGX-501 for the treatment of homozygous fami... 
Printer Friendly Version
03/06/17REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference
ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that Kenneth T. Mills, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. ET at the Boston Marriot... 
Printer Friendly Version
02/28/17REGENXBIO Honors Rare Disease Day® 2017
ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, joins the global rare disease community today in honoring Rare Disease Day® 2017, dedicated to raising awareness of rare diseases and their impact on the lives of patients and their families. This year’s theme, “Resear... 
Printer Friendly Version
02/28/17REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 7, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2016 and recent operational highlights. ... 
Printer Friendly Version
02/14/17REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration
Six leading U.S. retinal surgery centers expected to participate as enrollment sites in the trial Anticipate beginning trial enrollment by mid-2017; interim trial update expected by the end of 2017 ROCKVILLE, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announce... 
Printer Friendly Version
02/09/17REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the 6th Annual LEERINK Partners Global Healthcare Conference on Wednesday, February 15, 2017 at the Lotte New York Palace in New York City. A live webcast of REGENXBIO’s pre... 
Printer Friendly Version
02/02/17REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
ROCKVILLE, Md., Feb. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day. The conference will take place on Tuesday, February 14, 2017 at the JW Marriott Essex House New York in New York, NY. REG... 
Printer Friendly Version
01/06/17REGENXBIO Provides Year-End 2016 Corporate Update
Filed IND for RGX-314 Phase I clinical trial for wet AMD Announced initiation of protocol changes for RGX-501 Phase I/II clinical trial for HoFH; patient enrollment is now projected to begin first half 2017 Anticipate enrolling patients in clinical trials for three lead programs and filing an additional IND in 2017 Enhanced advanced manufacturing and analytics infrastructure and capabilities Ended 2016 with greater than $155 million in cash, cash equivalents and marketable securities... 
Printer Friendly Version